{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:12:47Z","timestamp":1761520367834,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clcc.2023.05.001","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T02:41:58Z","timestamp":1683772918000},"page":"291-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of Palliative Chemotherapy in Unresectable or Metastatic Colorectal Cancer Patients With Poor Performance Status"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7965-1356","authenticated-orcid":false,"given":"Lucila Soares","family":"da Silva Rocha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila Motta Venchiarutti","family":"Moniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilia Polo","family":"Mingueti e Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme Fialho","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virgilio","family":"Souza e Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Marcelo Gehm","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel P.","family":"Riechelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2023.05.001_bib0001","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.1998.16.1.301","article-title":"Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer","volume":"16","author":"Piedbois","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2023.05.001_bib0002","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/bmj.321.7260.531","article-title":"Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group","volume":"321","author":"Simmonds","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.clcc.2023.05.001_bib0003","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1200\/JCO.2008.20.2879","article-title":"Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer","volume":"27","author":"Sargent","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2023.05.001_bib0004","first-page":"52","article-title":"The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4","volume":"14","author":"Crosara Teixeira","year":"2015","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2023.05.001_bib0005","doi-asserted-by":"crossref","first-page":"e542s","DOI":"10.6061\/clinics\/2018\/e542s","article-title":"Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges","volume":"73","author":"Rocha","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.clcc.2023.05.001_bib0006","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1590\/S1983-14472013000200021","article-title":"Translation and cross-cultural adaptation of the Edmonton symptom assessment system for use in palliative care","volume":"34","author":"Monteiro","year":"2013","journal-title":"Rev Gaucha Enferm"},{"key":"10.1016\/j.clcc.2023.05.001_bib0007","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"volume":"2019","year":"2010","first-page":"2010","key":"10.1016\/j.clcc.2023.05.001_bib0008"},{"key":"10.1016\/j.clcc.2023.05.001_bib0009","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.clcc.2023.05.001_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jnci\/95.1.19","article-title":"Placebo effects in oncology","volume":"95","author":"Chvetzoff","year":"2003","journal-title":"J Natl Cancer Inst"},{"unstructured":"Ivanova A. UNC Lineberger comprehensive cancer center: Simon's two-stage design. 2019. http:\/\/cancer.unc.edu\/biostatistics\/program\/ivanova\/SimonsTwoStageDesign.aspx2014.","key":"10.1016\/j.clcc.2023.05.001_bib0011"},{"key":"10.1016\/j.clcc.2023.05.001_bib0012","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2023.05.001_bib0013","doi-asserted-by":"crossref","first-page":"756","DOI":"10.7326\/M20-1133","article-title":"A war on two fronts: cancer care in the time of COVID-19","volume":"172","author":"Kutikov","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clcc.2023.05.001_bib0014","doi-asserted-by":"crossref","first-page":"e21509","DOI":"10.1200\/JCO.2017.35.15_suppl.e21509","article-title":"End-of-life chemotherapy and adherence to ASCO's top five list recommendations: a single-center retrospective review","volume":"35","author":"Tancredi","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2023.05.001_bib0015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12904-019-0427-4","article-title":"Pimenta Riechelmann R. Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status","volume":"18","author":"Fiorin de Vasconcellos","year":"2019","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.clcc.2023.05.001_bib0016","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3892\/mco.2012.12","article-title":"Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: effectiveness and cost-utility analysis","volume":"1","author":"Nebuloni","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.clcc.2023.05.001_bib0017","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1","article-title":"Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial","volume":"40","author":"Yoshino","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2023.05.001_bib0018","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","article-title":"Prognostic Survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis","volume":"3","author":"Petrelli","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2023.05.001_bib0019","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2023.05.001_bib0020","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2023.05.001_bib0021","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2012.08.023","article-title":"Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin","volume":"49","author":"L\u00e1ng","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2023.05.001_bib0022","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/bmj.306.6880.752","article-title":"Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer","volume":"306","author":"Scheithauer","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/j.clcc.2023.05.001_bib0023","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/jco.2004.22.90140.3565","article-title":"5-Fluorouracil, folinic acid and oxaliplatin (FOLFOX) in poor prognosis patients with metastatic colorectal cancer","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2023.05.001_bib0024","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jpainsymman.2010.04.020","article-title":"A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients","volume":"41","author":"Watanabe","year":"2011","journal-title":"J Pain Symptom Manage"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282300035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282300035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:08:39Z","timestamp":1761520119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153300282300035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S153300282300035X"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2023.05.001","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Palliative Chemotherapy in Unresectable or Metastatic Colorectal Cancer Patients With Poor Performance Status","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2023.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}